Dongguang, China

Xiaoping Li

This inventor holds 1 USPTO granted patent. Top assignee: Sunshine Lake Pharma Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaoping Li. Retrieved from https://idiyas.com/inventor/xiaoping-li-dia0zghz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xiaoping Li: Innovator in Humanized Anti-TRKA Antibodies

Introduction

Xiaoping Li is a notable inventor based in Dongguang, China. She has made significant contributions to the field of biotechnology, particularly in the development of humanized anti-TRKA antibodies. Her work has the potential to impact therapeutic approaches for various medical conditions.

Latest Patents

Xiaoping Li holds a patent for "Humanized Anti-TRKA Antibodies and Uses Thereof." This patent represents her innovative approach to creating antibodies that can be utilized in medical treatments, showcasing her expertise in the field.

Career Highlights

Xiaoping Li is currently employed at Sunshine Lake Pharma Co., Ltd. Her role at the company allows her to engage in cutting-edge research and development, contributing to advancements in pharmaceutical sciences.

Collaborations

Xiaoping has collaborated with notable colleagues, including Zhiheng Ren and Junji Dong. These partnerships enhance her research efforts and foster innovation within her field.

Conclusion

Xiaoping Li's work in developing humanized anti-TRKA antibodies exemplifies her commitment to advancing medical science. Her contributions are paving the way for new therapeutic options and highlight the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…